IMPLEMENTING PHARMACOECONOMIC GUIDELINES IN ASIA: WILL
INCREASING EFFICIENCY HELP CONTAIN COSTS?
Auditorium
Budget constraints and growing public demand for
innovative drugs have made the efficient delivery of
quality health care a major priority worldwide. As a
result, an increasing number of countries have implemented
pharmacoeconomic guidelines and requirements.
As Asian health care systems move into an era of budget
constraints and rising pharmaceutical costs, many policy
makers are looking towards pharmacoeconomic requirements
as a cost control solution. But is pharmacoeconomics an
effective cost containment strategy?
A panel of global experts will discuss this pressing
question. Key opinion leaders from Asia will discuss the
anticipated impact of pharmacoeconomic requirements on
pharmaceutical spending in the region. Experts from
Europe, Australia and Asia will explore the evolution of
pharmacoeconomic requirements and discuss their value in
containing pharmaceutical spending.
|
Panel chair: |
Professor Lieven Annemans, MSc, PhD
Principal, Health Economics and Outcomes Research
HEDM, a unit of IMS Health, Belgium and Professor Health
Economics Ghent University, Belgium |
|
Panel member: |
Peter Davey, BA (Ec), MA (Ec)
Principal, Health Economics and Outcomes Research
M-TAG, a unit of IMS Health, Australia
Pharmacoeconomic guidelines: examining their success in
containing costs in Europe and Asia
What has been the impact of pharmacoeconomic guidelines in
Europe and Australia? Have pharmacoeconomic guidelines
increased efficiency or contained costs? Mr Davey will
explore the evolution of pharmacoeconomic requirements in
Europe and Australia and discuss their value in containing
pharmaceutical spending. |
|
Panel members: |
Eun Young Bae, PhD
Senior Researcher, Research Department
Korean Health Insurance Review Agency
Implementing pharmacoeconomic guidelines in Korea: what
are HIRA’s expectations?
Interest in the use of economic evaluation in Korea has
been growing since the financial crisis of the Korean
National Health Insurance fund in 2001. Korea is one of
the first countries in the region to consider mandating
that pharmaceutical companies submit the results of an
economic evaluation when seeking reimbursement for new
pharmaceuticals. Dr. Bae will discuss the proposed
guidelines and the government’s expectations regarding the
impact these guidelines will have on the Korean
pharmaceutical budget and the efficient allocation of
government resources. |
|
|
Mi-Won Han, pharmacist, BA
Health Economics and Epidemiology Manager
Scientific Affairs Department
Sanofi-Aventis Korea
Efficiency tool or cost containment mechanism: a
pharmaceutical industry view on the impact of the
implementation of pharmacoeconomic guidelines in Asia.
A mandatory requirement to submit economic evaluations
with reimbursement applications poses a “fourth hurdle”
for pharmaceutical companies that want to obtain
reimbursement for their product. Ms Han will discuss how
the industry views the implementation of pharmacoeconomic
guidelines in Korea and across the Asia region.
|
|
|
Shu Chuen Li, BPharm, MAppSci, MBA, PhD
Associate Professor
Department of Pharmacy
National University of Singapore
Implementing pharmacoeconomic guidelines in Asia: theories
and practicalities
Professor Li will offer a regional perspective on the
subject and provide an academic view on the strength of
government and industry arguments. |
Professor Lieven Annemans MSc, PhD
Principal, Health Economics and Outcomes Research
HEDM, a unit of IMS Health
MeiseBrussels, Belgium, and Professor Health Economics,
Ghent University, Belgium
E-mail: Lannemans@be.imshealth.com
Professor Annemans is Principal, Health Economics and
Outcomes Research at IMS Health in Brussels. He helps
clients to determine cost of illness, evaluate treatment
outcomes and budgetary impact, understand European
healthcare practices and policies, and designs and
analyses prospective studies.
A health economist by training, Lieven has a background in
the pharmaceutical industry gained in roles in market
research and health economic functions at Lilly, Pfizer
and Janssen. Over the course of his career, he has
conducted health economic evaluations in numerous
countries across a range of therapeutic areas.
A former president of ISPOR, Lieven has been Professor of
Health Economics at Ghent University since February 2001,
is a Chairman of the Flemish Health Council and a member
of the boards of the Belgium Society for Pharmaco-epidemiology
and the Belgium Society for Health Economics. He is also a
former advisor to the Minister of Public Health.
Peter Davey, BA (Ec), MA (Ec)
Principal, Health Economics and Outcomes Research
M-TAG, a unit of IMS Health
Sydney, Australia
Tel: 61-2-9419-7722
Fax: 61-2-9419-7922
Email: pdavey@m-tag.net
Peter Davey is Principal, Health Economics and Outcomes
Research, Asia Pacific and Japan at IMS. Peter was
formerly on staff at the Centre for Health Economics
Research and Evaluation at the University of Sydney and is
currently involved in teaching the postgraduate program in
Drug Development at the University of NSW. He has worked
internationally as a consultant to the health care
industry since 1992 and co-founded M-TAG Pty Ltd in 1995.
Peter’s expertise encompasses a broad range of techniques
used in health technology assessment and economic
evaluation, including valuation techniques,
decision-analytic modelling, development of trial
protocols and health services and policy-based research.
He has a special interest in the use of evidence based
medicine and economic evaluation in healthcare decision
making and has presented widely at conferences on health
technology assessment issues.
Eun Young Bae, PhD
Senior Researcher, Research Department
Health Insurance Review Agency
Seoul, Korea
Tel: 82-2-705-6994
Fax: 82-2-585-6918
Email: eybae21@hiramail.net
Dr Bae is a Senior Researcher at the Korean Health
Insurance Review Agency (HIRA), where she has been
involved in drafting pharmacoeconomic guidelines for
Korea. Before joining HIRA, Dr Bae worked as a Research
Assistant at the Korean Institute for Health and Social
Welfare.
Mi-Won Han, pharmacist, BA
Health Economics & Epidemiology
Scientific Affairs Department
Sanofi-Aventis Korea
Tel: 82-2-527-5059
Fax: 82-2-527-5551
Email: mi-won.han@sanofi-aventis.com
Ms Han is the Health Economics and Epidemiology Manager
for Sanofi-Aventis Korea. Over the course of her career at
Sanofi-Aventis and Youngjin Pharmaceutical Co., Ltd, Ms
Han has been involved in the registration of
pharmaceutical products, as well as pricing and
reimbursement applications in Korea. Ms. Han attended the
College of Pharmacology at Chosun University.
Shu Chuen Li, BPharm, MAppSci, MBA, PhD
Department of Pharmacy
National University of Singapore
Science Drive 4
Singapore 117543
Tel: 6516 6537
Fax: 6779 1554
Email: phalisc@nus.edu.sg
Dr Li is an Associate Professor in the Department of
Pharmacy at the National University of Singapore. Dr Li
works as a consultant for various multinational
pharmaceutical companies. He is currently serving as a
part-time consultant/visiting specialist for the Centre of
Pharmaceutical Administration, Health Sciences Authority
and consultant to the Pharmacy & Therapeutics Committee of
National Healthcare Group.
Dr Li graduated BPharm and MAppSci from the University of
South Australia, Adelaide and was admitted to the degree
of PhD by Monash University, Australia. Dr Li also holds a
Certificate of Health Economics from Monash University and
a Graduate Diploma in Business (Technology Management) and
MBA from Deakin University.
|
